Description

Simple

An antibiotic used to treat a wide variety of infections in the body.

Clinical

A glycylcycline antibiotic used to treat a number of susceptible bacterial infections.

Overview

Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.

Pharmacology

Indication

For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus Read more

Pharmacodynamic

Tigecycline is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. Glycylcyclines are a new class of antibiotics derived from tetracycline. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, na... Read more

Mechanism of action

Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a gly... Read more

Absorption

Information currently not available.

Protein binding

71% to 89%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

27-43 hours

Route of elimination

Information currently not available.

Toxicity

Since glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Tigecycline
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Tigecycline.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Tigecycline.
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Tigecycline is combined with 4-hydroxycoumarin.
4-Oxoretinol
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when 4-Oxoretinol is combined with Tigecycline.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Tigecycline.
Acetylcysteine zinc
Acetylcysteine zinc can cause a decrease in the absorption of Tigecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acetyldigoxin
Tigecycline can cause an increase in the absorption of Acetyldigoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
Acitretin
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Acitretin is combined with Tigecycline.
Alcuronium
The therapeutic efficacy of Alcuronium can be increased when used in combination with Tigecycline.
Alitretinoin
The risk or severity of pseudotumor cerebri and elevated intracranial pressure can be increased when Alitretinoin is combined with Tigecycline.
Allylestrenol
The serum concentration of Allylestrenol can be decreased when it is combined with Tigecycline.
Altrenogest
The serum concentration of Altrenogest can be decreased when it is combined with Tigecycline.
Amdinocillin
The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Tigecycline.
Amoxicillin
The therapeutic efficacy of Amoxicillin can be decreased when used in combination with Tigecycline.
Ampicillin
The therapeutic efficacy of Ampicillin can be decreased when used in combination with Tigecycline.
Apramycin
The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Apramycin.
Arbekacin
The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Arbekacin.
Aspoxicillin
The therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Tigecycline.
Atracurium
The therapeutic efficacy of Atracurium can be increased when used in combination with Tigecycline.
Atracurium besylate
The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tigecycline.
2 References
  1. 1 . Rose WE, Rybak MJ: Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.PubMed: 16863487
  2. 2 . Kasbekar N: Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm. 2006 Jul 1;63(13):1235-43.PubMed: 16790575